

Galápagos

Introduction to Galapagos

PMI Chapter Event

Imme Van der Taelen, PMP

June 12, 2019



Who we are

- We are a biotechnology company that creates value through science
- Our mission is to become a fully integrated biopharma company in 2020
- Our strategy to get there is through discovering and developing novel mode-of-action medicines and deliver them to the world
- Proof of our target discovery approach: filgotinib in inflammatory diseases, GLPG1690 in idiopathic pulmonary disease, MOR106 in atopic dermatitis





Basics

Founded

in 1999 by Onno van de Stolpe

Headquarters

Mechelen, Belgium


Galapagos R&D

Belgium, The Netherlands,
France, USA, Switzerland

Service Operation Fidelta


Zagreb, Croatia

Note: All values as per 31-03-2019






Employees per site



Note: All values as per 31-12-2018



In twenty years time



Unique target discovery engine



NOVEL TARGETS

disease-modifying
multiple disease areas
first-in-class candidates



SMART DEVELOPMENT

rapid, multiple PoCs
swift moves to pivotal
development




3 PROOFS OF CONCEPT

filgotinib (JAK1)
'1690 (autotaxin)
MOR106 (IL17-C)




R&D ambition





Business strategy

We focus on developing novel mode-of-action medicines and deliver them to the world





2019 pipeline

Area	Preclinical	Phase 1	Phase 2	Phase 3
Filgotinib	10+ indications			
IPF/fibrosis	'1690, '1205			
OA	'1972			
AtD	MOR106			
Inflammation Fibrosis	>20 programs			

More than 40 clinical trials planned in 2019